Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.22 Billion INR | 59.85% |
| 2022 | 133.91 Million INR | 0.81% |
| 2021 | 132.83 Million INR | 52.9% |
| 2020 | 86.87 Million INR | 185.41% |
| 2019 | -101.71 Million INR | 55.92% |
| 2018 | -230.75 Million INR | 61.87% |
| 2017 | -605.24 Million INR | 82.68% |
| 2016 | -3.49 Billion INR | -80.73% |
| 2015 | -1.93 Billion INR | -94.51% |
| 2014 | -993.77 Million INR | -231.56% |
| 2013 | -299.72 Million INR | -73.54% |
| 2012 | -172.71 Million INR | 0.0% |
| 2010 | 1.16 Billion INR | 43.21% |
| 2009 | 813.14 Million INR | 5.18% |
| 2008 | 773.07 Million INR | 10.92% |
| 2007 | 696.97 Million INR | 46.83% |
| 2006 | 474.69 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -21.49 Million INR | -128.23% |
| 2023 FY | 214.06 Million INR | 59.85% |
| 2023 Q4 | 76.11 Million INR | 432.47% |
| 2023 Q3 | -22.89 Million INR | -151.94% |
| 2023 Q2 | 44.07 Million INR | -62.26% |
| 2023 Q1 | 116.77 Million INR | 1529.29% |
| 2022 Q4 | 7.16 Million INR | -93.24% |
| 2022 Q3 | 106.04 Million INR | 180.03% |
| 2022 Q2 | 37.86 Million INR | 301.43% |
| 2022 Q1 | -18.8 Million INR | -212.11% |
| 2022 FY | 133.91 Million INR | 0.81% |
| 2021 Q3 | 40.45 Million INR | -14.67% |
| 2021 Q1 | 28.13 Million INR | 132.01% |
| 2021 Q2 | 47.41 Million INR | 68.5% |
| 2021 FY | 132.83 Million INR | 52.9% |
| 2021 Q4 | 16.76 Million INR | -58.55% |
| 2020 FY | 86.87 Million INR | 185.41% |
| 2020 Q1 | 43.67 Million INR | -33.71% |
| 2020 Q2 | 89.09 Million INR | 103.97% |
| 2020 Q3 | 107.05 Million INR | 20.16% |
| 2020 Q4 | -87.9 Million INR | -182.11% |
| 2019 FY | -101.71 Million INR | 55.92% |
| 2019 Q3 | 69.64 Million INR | 2637.66% |
| 2019 Q4 | 65.88 Million INR | -5.4% |
| 2019 Q1 | -16.32 Million INR | 79.67% |
| 2019 Q2 | 2.54 Million INR | 115.59% |
| 2018 FY | -230.75 Million INR | 61.87% |
| 2018 Q3 | -77.6 Million INR | -85.85% |
| 2018 Q4 | -80.28 Million INR | -3.46% |
| 2018 Q2 | -41.75 Million INR | -160.82% |
| 2018 Q1 | 68.65 Million INR | -4.12% |
| 2017 Q4 | 71.6 Million INR | 683.22% |
| 2017 Q1 | -115.24 Million INR | 85.87% |
| 2017 FY | -605.24 Million INR | 82.68% |
| 2017 Q3 | 9.14 Million INR | 0.0% |
| 2016 Q1 | -212.47 Million INR | 81.73% |
| 2016 Q3 | -1.82 Billion INR | -183.51% |
| 2016 Q2 | -642.36 Million INR | -202.33% |
| 2016 Q4 | -815.83 Million INR | 55.2% |
| 2016 FY | -3.49 Billion INR | -80.73% |
| 2015 FY | -1.93 Billion INR | -94.51% |
| 2015 Q2 | -165.99 Million INR | 30.51% |
| 2015 Q4 | -1.16 Billion INR | -435.03% |
| 2015 Q3 | -217.41 Million INR | -30.98% |
| 2015 Q1 | -238.85 Million INR | 45.61% |
| 2014 Q2 | -153.25 Million INR | -49.21% |
| 2014 FY | -993.77 Million INR | -231.56% |
| 2014 Q4 | -439.19 Million INR | -5.33% |
| 2014 Q3 | -416.97 Million INR | -172.09% |
| 2014 Q1 | -102.71 Million INR | -106.26% |
| 2013 Q2 | -197.53 Million INR | -21.2% |
| 2013 FY | -299.72 Million INR | -73.54% |
| 2013 Q1 | -162.98 Million INR | 6.19% |
| 2013 Q3 | -80.27 Million INR | 59.36% |
| 2013 Q4 | -49.79 Million INR | 37.97% |
| 2012 Q4 | -173.75 Million INR | -16.93% |
| 2012 FY | -172.71 Million INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 28.03 Million INR | 0.0% |
| 2012 Q3 | -148.6 Million INR | -630.13% |
| 2010 FY | 1.16 Billion INR | 43.21% |
| 2009 FY | 813.14 Million INR | 5.18% |
| 2008 FY | 773.07 Million INR | 10.92% |
| 2007 FY | 696.97 Million INR | 46.83% |
| 2006 FY | 474.69 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 78.709% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 97.095% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 86.347% |
| Granules India Limited | 6.81 Billion INR | 82.015% |
| Indoco Remedies Limited | 1.29 Billion INR | 5.151% |
| Achyut Healthcare Limited | 4.43 Million INR | -27524.245% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.77% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.701% |
| Alpa Laboratories Limited | 184.49 Million INR | -564.49% |
| Brooks Laboratories Limited | 14.44 Million INR | -8390.055% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 28.619% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 0.409% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.19% |
| Eris Lifesciences Limited | 5.18 Billion INR | 76.341% |
| FDC Limited | 2.98 Billion INR | 58.946% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 81.146% |
| Gufic Biosciences Limited | 1.32 Billion INR | 7.816% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 72.267% |
| Ipca Laboratories Limited | 7.98 Billion INR | 84.638% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -141.27% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 906.783% |
| Lasa Supergenerics Limited | -458 Million INR | 367.675% |
| Laurus Labs Limited | 3.94 Billion INR | 68.952% |
| Lupin Limited | 28.04 Billion INR | 95.629% |
| Mankind Pharma Limited | 21.51 Billion INR | 94.303% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1122.297% |
| Megasoft Limited | -121.1 Million INR | 1112.323% |
| NATCO Pharma Limited | 25.96 Billion INR | 95.278% |
| Piramal Pharma Limited | 4.55 Billion INR | 73.097% |
| RPG Life Sciences Limited | 2.29 Billion INR | 46.518% |
| Sigachi Industries Limited | 1.47 Billion INR | 16.822% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.825% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 73.393% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -391.859% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -115.189% |
| Windlas Biotech Limited | 1.29 Billion INR | 5.614% |
| ZIM Laboratories Limited | 253.82 Million INR | -382.988% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 97.156% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 129.792% |
| Divi's Laboratories Limited | 33.08 Billion INR | 96.294% |
| Hester Biosciences Limited | 364.81 Million INR | -236.055% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 55.996% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -167.945% |
| Bal Pharma Limited | 233.9 Million INR | -424.12% |
| Strides Pharma Science Limited | 5.22 Billion INR | 76.54% |
| Venus Remedies Limited | 534.65 Million INR | -129.302% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 60.808% |
| Nectar Lifesciences Limited | 923.8 Million INR | -32.708% |
| Shilpa Medicare Limited | 1.36 Billion INR | 10.269% |
| Aarti Drugs Limited | 7.14 Billion INR | 82.851% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 23.224% |
| Suven Life Sciences Limited | -1.22 Billion INR | 200.012% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 91.417% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 131.819% |
| Themis Medicare Limited | 392.58 Million INR | -212.277% |
| Hikal Limited | 32.11 Million INR | -3718.013% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 95.161% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -95.685% |
| Wockhardt Limited | -670 Million INR | 282.98% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 76.374% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -13418.63% |
| Neuland Laboratories Limited | 5.31 Billion INR | 76.947% |
| Morepen Laboratories Limited | 4.17 Billion INR | 70.627% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -489.264% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4364.87% |